Navigation Links
Massachusetts Patients Offer Feedback on Their Experiences With Primary Care
Date:7/10/2008

well physicians' offices handle patients' access, service and care needs, such as:

-- whether patients feel they get timely appointments, care and information,

-- how well other clinicians in the practice cared for them, and

-- what level of service they get from office staff.

A sample of the statewide findings includes:

-- 67 % of adult patients and 73% of parents of child patients reported that their doctor always seemed to know the important information about their medical history.

-- Almost 70% of patients reported that someone from their doctor's office always followed up with test results for themselves or their child.

-- 60% of patients (adult and child) reported that their doctor was always informed and up to date about the care they received from specialists.

-- 54% of adult patients and 78% of parents of child patients reported that when they called the doctor's office with a medical question during regular office hours, they always got an answer to their question the same day.

MHQP's first statewide survey of patients' experiences with primary care physicians was released in March 2006.


'/>"/>
SOURCE Massachusetts Health Quality Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Massachusetts State Court Hears Suit by Breastfeeding Mother on Medical Licensing Exam
2. Massachusetts Employers and Health Plans Continue to Support Quality Care by Rewarding Physicians through Bridges to Excellence Programs
3. NBME Appeals Massachusetts Judges Reversal of Lower Court in Suit for Extra Break Time During Medical Licensing Exam
4. AIDS Action Committee Testifies to Protect the Privacy of People Seeking Healthcare in Massachusetts
5. Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System
6. Massachusetts Mandatory Health Insurance Purchase Law is No Model for California
7. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
8. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
9. Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Councils Ninth Annual MASS Opportunities Investment Conference
10. Consumer Group to Nunez: Massachusetts Mandatory Health Insurance Purchase Law Is No Model for California
11. Lung Cancer Alliance Hails Massachusetts Senator for Taking Lead on Lung Cancer Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Sermo ( http://www.sermo.com ), the world,s ... results of a new Sermo Vitals Report titled ... The report examines physician dialog about diabetes over ... of a variety of topics, including the therapies ... and candid/verbatim comments on issues related to diabetes. ...
(Date:12/16/2009)... WILMINGTON, Delaware, December 16 While ... outsource their accurate forecast models,for new and ... provides,integrated patient-based forecast solutions to various players. ... I, phase II, as well as phase,III. ... launch, product life cycle,management, market entry strategy, ...
(Date:12/16/2009)... Study finds 6- to 11-month interval lessens complication risks , , ... bundle of joy has had such a profound impact on ... take a breath. A new study suggests that you ... pregnant again, and that more than 11 months could be ... interval between pregnancies was less than six months, the chances ...
(Date:12/16/2009)... visitors can earn a free 21-count one week trial bottle sample ... ... MI (PRWEB) December 16, 2009 -- ImmuneResponse247.com announces ... Sample” of Immune Response 247™ 6 Mushroom Formula , with ... Immune Response 247™ 6 Mushroom Formula is packaged in FDA approved ...
(Date:12/16/2009)... The cost of hearing aids has been brought into reach for ... new subscription based hearing plan. , ... (PRWEB) December ... into reach for many Houstonians with the announcement by Hearing Haven, ... benefit by hearing better on the job, and want to improve ...
Breaking Medicine News(10 mins):Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 2Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 3Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Monthly Subscription Hearing Aid Plan Announced for Houston 2
... Lee Baca has justified placing Paris Hilton under house arrest ... seems that Judge Michael T Sauer who ordered her ... was conning doctors. ,On Larry Kings show, Larry Waldie, ... that Sauer didn't care, and that he even hinted that ...
... Many a families summer vacations mean piling into the car ... marred by frequent nausea and vomiting . This means some ... ,Carsickness, a variant of motion sickness, happens when the ... fast and in what direction the body is moving, says ...
... a clinical stage biopharmaceutical company developing targeted monoclonal ... C virus infection, today announced initiation of ... safety and efficacy of its tumor necrosis therapy ... (GBM), a deadly form of brain cancer. ...
... I trials studying REP8839, a novel topical antibiotic that ... skin pathogens including methicillin-resistant S. aureus (MRSA). ... topically applied REP8839 appears safe, well-tolerated and associated with ... which is desirable for a topical antibiotic treatment. Based ...
... Accera, Inc. announced today that recent data from its Phase ... AD may effectively be thought of and treated as diabetes ... to be caused by the accumulation of amyloid beta plaques ... shown that inducing insulin resistance in the brains of mice ...
... drug, Gatifloxacin, is a better treatment for drug- resistant ... a team of researchers led by Dr Buddha Basnyat ... ,As part of the study, researchers compared the effect ... recommended by the World Health Organisation for treating enteric ...
Other Medicine News:Health News:Car Sickness for the Little Ones can Be Prevented 2Health News:Car Sickness for the Little Ones can Be Prevented 3Health News:Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial 2Health News:Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2
(Date:12/16/2009)... VIEW, Calif., Dec. 16 ChemoCentryx, Inc. ... in a Phase 2 clinical trial of CCX354, ... specifically target the CCR1 chemokine receptor for the ... is a highly potent and selective antagonist of ... of immune cells, such as monocytes and macrophages, ...
(Date:12/16/2009)... , ... Recruits a Total of Over,640 patients Ahead ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical ... innovative treatments for eye,disease, vascular disease and ... enrolment of the second Phase III trial ...
(Date:12/15/2009)... Volcano Corporation (Nasdaq: VOLC ), ... tools - including Fractional Flow Reserve (FFR), Intravascular ... Tomography (OCT) - designed to enhance the diagnosis ... announced today the placement of over 2,500 s5 ... consoles was first launched in April 2006, with ...
Breaking Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Volcano Announces Installed Base Growth Milestone 2Volcano Announces Installed Base Growth Milestone 3Volcano Announces Installed Base Growth Milestone 4Volcano Announces Installed Base Growth Milestone 5Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 1Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 2Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 3Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 4Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 5Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 6BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 1BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 2BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 3BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 4Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research 6853 1Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research 6853 2
... participates in a national study to explore new ... Jan. 12 Reproductive Partners Medical Group ... for their excellent IVF success rates and national ... a national, multi-center study exploring new progesterone delivery ...
... (Nasdaq: IDIX ), a biopharmaceutical company engaged ... treatment of human viral and other infectious diseases, today ... IDX184, a liver-targeted nucleotide prodrug candidate for the treatment ... with the U.S. Food and Drug Administration (FDA). The ...
Other Medicine Technology:Reproductive Partners Participates in New IVF Progesterone Delivery System Study 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4
... aqueous samples of moderate viscosity and density. Proven ergonomic design reduces hand ... Volume Range (ul) ... 1.0~2.0 Imprecision(%) ... 1 ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: